BR9916477A - Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos - Google Patents

Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos

Info

Publication number
BR9916477A
BR9916477A BR9916477-9A BR9916477A BR9916477A BR 9916477 A BR9916477 A BR 9916477A BR 9916477 A BR9916477 A BR 9916477A BR 9916477 A BR9916477 A BR 9916477A
Authority
BR
Brazil
Prior art keywords
composition
polynucleotide
polynucleotides
vaccine
disclosed
Prior art date
Application number
BR9916477-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Josee Hamel
Bernard R Brodeur
Clement Rioux
Isabelle Pineau
Denis Martin
Nathalie Charland
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of BR9916477A publication Critical patent/BR9916477A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR9916477-9A 1998-12-23 1999-12-20 Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos BR9916477A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
PCT/CA1999/001218 WO2000039299A2 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Publications (1)

Publication Number Publication Date
BR9916477A true BR9916477A (pt) 2004-06-22

Family

ID=22351610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916477-9A BR9916477A (pt) 1998-12-23 1999-12-20 Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos

Country Status (29)

Country Link
EP (2) EP1141306B1 (enExample)
JP (2) JP4761623B2 (enExample)
KR (4) KR101078919B1 (enExample)
CN (3) CN101134775A (enExample)
AP (1) AP2001002199A0 (enExample)
AR (1) AR029322A1 (enExample)
AT (1) ATE394489T1 (enExample)
AU (1) AU1764900A (enExample)
BR (1) BR9916477A (enExample)
CA (1) CA2356836C (enExample)
CL (1) CL2009002037A1 (enExample)
CY (3) CY1108223T1 (enExample)
CZ (2) CZ303675B6 (enExample)
DE (1) DE69938670D1 (enExample)
DK (3) DK1141306T3 (enExample)
EA (1) EA007409B1 (enExample)
ES (3) ES2480417T3 (enExample)
HU (1) HU229664B1 (enExample)
IL (3) IL143905A0 (enExample)
MX (1) MXPA01006427A (enExample)
NO (1) NO330800B1 (enExample)
NZ (1) NZ512574A (enExample)
OA (1) OA11736A (enExample)
PL (3) PL206576B1 (enExample)
PT (3) PT1141306E (enExample)
TR (2) TR200200633T2 (enExample)
UY (1) UY25877A1 (enExample)
WO (1) WO2000039299A2 (enExample)
ZA (1) ZA200105114B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2000001886A0 (en) 1998-02-20 2000-09-30 Iaf Biochem Int Group B streptococcus antigens.
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
EA007409B1 (ru) * 1998-12-23 2006-10-27 Шайе Биокем Инк. Антигенные полипептиды стрептококков, способы их получения и применения
DE60136356D1 (de) * 2000-06-12 2008-12-11 Univ Saskatchewan Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
EP2281891A3 (en) * 2000-06-20 2011-08-17 ID Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
WO2002079475A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
AU2002317107B2 (en) 2001-07-06 2008-06-12 Id Biomedical Corporation Group B streptococcus antigens and corresponding DNA fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
AU2004218284B2 (en) 2003-03-04 2009-07-23 Intercell Ag Streptococcus pyogenes antigens
EP2311987A1 (en) * 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
DK2384765T3 (en) 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
ES2397488T3 (es) * 2007-07-23 2013-03-07 Sanofi Pasteur Limited Polipéptidos inmunógenos y anticuerpos monoclonales
ES2678694T3 (es) 2008-04-16 2018-08-16 Glaxosmithkline Biologicals Sa Vacuna
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP3358008A1 (en) 2009-09-03 2018-08-08 Pfizer Vaccines LLC Pcsk9 vaccine
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20140009281A (ko) 2010-12-03 2014-01-22 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
MY163871A (en) * 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2859078A1 (en) * 2012-01-05 2013-07-11 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
HRP20211288T1 (hr) 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096783T (pt) 2014-01-21 2021-08-16 Pfizer Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3443983B1 (en) 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220265803A1 (en) 2019-07-31 2022-08-25 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
IL295632A (en) 2020-02-23 2022-10-01 Pfizer Escherichia coli preparations and their methods
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2025508749A (ja) 2022-01-13 2025-04-10 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CA3256617A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
PE20251701A1 (es) 2022-11-22 2025-07-02 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE69432658T2 (de) * 1993-03-19 2004-04-08 Gunnar Lindahl Rib-protein, ein oberflächenprotein welches immunität gegen viele streptococcus-stämme der gruppe b verleiht, reinigungsverfahren für das rib-protein, testsatz und pharmazeutische zusammenstellung (arznei)
WO1996040928A1 (en) * 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US6420135B1 (en) * 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
CA2305016A1 (en) * 1997-09-24 1999-04-01 Regents Of The University Of Minnesota Human complement c3-degrading proteinase from streptococcus pneumoniae
AU770378B2 (en) * 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
ATE361365T1 (de) * 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
BR9914066A (pt) * 1998-09-24 2002-04-23 Univ Minnesota Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
US6582706B1 (en) * 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
EA007409B1 (ru) * 1998-12-23 2006-10-27 Шайе Биокем Инк. Антигенные полипептиды стрептококков, способы их получения и применения

Also Published As

Publication number Publication date
JP2002533123A (ja) 2002-10-08
KR20100063814A (ko) 2010-06-11
IL194230A (en) 2013-12-31
NO20013045D0 (no) 2001-06-19
NO20013045L (no) 2001-08-20
HU229664B1 (en) 2014-04-28
CN1332803A (zh) 2002-01-23
KR101078919B1 (ko) 2011-11-01
ES2480417T3 (es) 2014-07-28
KR20080036666A (ko) 2008-04-28
HUP0104774A2 (hu) 2002-04-29
PT1141306E (pt) 2008-07-30
EA007409B1 (ru) 2006-10-27
CN1191362C (zh) 2005-03-02
NZ512574A (en) 2004-03-26
KR20060134227A (ko) 2006-12-27
EP2261358B1 (en) 2014-05-14
IL143905A (en) 2011-05-31
EP2261358A3 (en) 2011-02-23
CY1108223T1 (el) 2014-02-12
EP1141306A2 (en) 2001-10-10
CN100398653C (zh) 2008-07-02
CZ20012161A3 (cs) 2001-10-17
ES2306528T3 (es) 2008-11-01
IL194230A0 (en) 2011-08-01
DK1950302T3 (da) 2013-01-14
CY1114722T1 (el) 2016-10-05
JP2010142246A (ja) 2010-07-01
PL206576B1 (pl) 2010-08-31
EP1141306B1 (en) 2008-05-07
CY1115340T1 (el) 2017-01-04
JP5039802B2 (ja) 2012-10-03
PL349777A1 (en) 2002-09-09
CZ303675B6 (cs) 2013-02-27
CA2356836C (en) 2011-09-13
NO330800B1 (no) 2011-07-18
CL2009002037A1 (es) 2010-06-25
DK2261358T3 (da) 2014-07-28
EP2261358A2 (en) 2010-12-15
AP2001002199A0 (en) 2001-09-30
KR100891398B1 (ko) 2009-04-02
AR029322A1 (es) 2003-06-25
WO2000039299A3 (en) 2000-11-02
OA11736A (en) 2005-06-12
ATE394489T1 (de) 2008-05-15
DK1141306T3 (da) 2008-08-18
KR100802198B1 (ko) 2008-02-11
DE69938670D1 (de) 2008-06-19
PL205041B1 (pl) 2010-03-31
TR200200633T2 (tr) 2002-06-21
AU1764900A (en) 2000-07-31
CZ302790B6 (cs) 2011-11-09
IL143905A0 (en) 2002-04-21
ES2400280T3 (es) 2013-04-08
PL204073B1 (pl) 2009-12-31
JP4761623B2 (ja) 2011-08-31
HK1118575A1 (en) 2009-02-13
KR101170203B1 (ko) 2012-07-31
PT1950302E (pt) 2013-01-16
EA200100565A1 (ru) 2002-04-25
WO2000039299A2 (en) 2000-07-06
CA2356836A1 (en) 2000-07-06
ZA200105114B (en) 2002-11-21
HUP0104774A3 (en) 2007-10-29
MXPA01006427A (es) 2002-06-04
KR20010104693A (ko) 2001-11-26
CN1654657A (zh) 2005-08-17
UY25877A1 (es) 2000-08-21
PT2261358E (pt) 2014-07-30
CN101134775A (zh) 2008-03-05
TR200102497T2 (tr) 2002-01-21

Similar Documents

Publication Publication Date Title
BR9916477A (pt) Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos
MXPA03000103A (es) Antigenos de streptococcus.
AP2000001886A0 (en) Group B streptococcus antigens.
BR0015137A (pt) Peptìdeos antigênicos de neisseria
BR0208944A (pt) quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos
ATE479756T1 (de) Streptococcus pneumoniae-antigene und impfstoffe
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
AR003124A1 (es) Proteinas estreptococicas de shock termico miembros de la familia de hsp7270,secuencia de adn que codifica para dichos polipeptidos, vector deexpresion, molecula de adn recombinante, metodo para producir un polipeptido o fragmento del mismo, anticuerpo o fragmento del mismo y anticuerpo monoclonal,
NO20012812L (no) Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid
ATE323721T1 (de) Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
ATE382055T1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
Meehan et al. Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with Streptococcus equi subsp. equi
NO20011381L (no) Preparater av streptokokk C<beta>-protein
FR2766193B1 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
BR0108654A (pt) Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
WO2002057315A3 (en) Streptococcal streptolysin s vaccines
BR9908476A (pt) Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae
DK0917471T3 (da) Behandling og diagnose af grampositive kokinfektioner
MX9805158A (es) Adn que codifica una proteina activadora de plasminogeno.
BR0111886A (pt) Antìgeno para estreptococos
EP1950302A3 (en) Streptococcus antigens
ATE547527T1 (de) Gruppe b streptococcus bvh-a2 und bvh-a3 antigene
ATE341613T1 (de) Fluordesoxyuridin-resistente streptococcus gordonii stämme

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: TRANSFERIDO DE: SHIRE BIOCHEM INC.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA E ALTERACAO DE SEDE NO 020050112625/RJ DE 11/10/2005, POIS TAL ATO JA FOI DEFERIDO E PUBLICADO NA RPI 1849 DE 13/06/2006.

B25G Requested change of headquarter approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070101374/RJ DE 24/07/2007.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (IX), 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O MESMO DEVERA APRESENTAR DECLARACAO CONFORME ARTO 10 DA RESOLUCAO 81/2013 DE 28/03/2013.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A EXIGENCIA PUBLICADA NA RPI 2254 DE 18/03/2014, POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time